​

Amgen (AMGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMGN Stock Forecast

Amgen (AMGN) stock forecast, based on 31 Wall Street analysts, predicts a 12-month average price target of $304.67, with a high of $315.00 and a low of $294.00. This represents a 2.48% increase from the last price of $297.29.

$260 $275 $290 $305 $320 $335 High: $315 Avg: $304.67 Low: $294 Last Closed Price: $297.29

AMGN Stock Rating

Amgen stock's rating consensus is Buy, based on 31 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (70.97%), 8 Hold (25.81%), 1 Sell (3.23%), and 0 Strong Sell (0.00%).

Buy
Total 31 1 8 22 Strong Sell Sell Hold Buy Strong Buy

AMGN Price Target Upside V Benchmarks

TypeNameUpside
StockAmgen2.48%
SectorHealthcare Stocks 23.68%
IndustryDrug Manufacturers - General Stocks20.05%

Price Target Trends

1M3M12M
# Anlaysts-214
Avg Price Target-$310.00$328.07
Last Closing Price$297.29$297.29$297.29
Upside/Downside-4.28%10.35%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25510142132
May, 2559152132
Apr, 2559142131
Mar, 2559142131
Feb, 25510142132
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 02, 2025Trung HuynhUBS$315.00$281.2212.01%5.96%
Apr 22, 2025Cantor Fitzgerald$305.00$278.409.55%2.59%
Mar 05, 2025Johnson Rice$294.00$316.57-7.13%-1.11%
Nov 12, 2024Michael YeeJefferies$380.00$298.8427.16%27.82%
Nov 12, 2024Olivia BrayerCantor Fitzgerald$405.00$298.8435.52%36.23%
Oct 21, 2024Terence FlynnMorgan Stanley$319.00$316.740.71%7.30%
Oct 16, 2024Salveen RichterGoldman Sachs$369.00$325.0913.51%24.12%
Oct 07, 2024Carter GouldBarclays$315.00$319.66-1.46%5.96%
Sep 25, 2024Evan David SeigermanBMO Capital$362.00$330.929.39%21.77%
Sep 25, 2024Christopher RaymondRaymond James$344.00$330.923.95%15.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 02, 2025Morgan StanleyEqual-WeightEqual-Weighthold
Apr 22, 2025Cantor FitzgeraldOverweightNeutraldowngrade
Feb 12, 2025Piper SandlerOverweightOverweighthold
Feb 05, 2025CitigroupNeutralNeutralhold
Nov 27, 2024Cowen & Co.BuyBuyhold
Nov 13, 2024CitigroupNeutralinitialise
Nov 12, 2024BMO CapitalOutperformOutperformhold
Nov 12, 2024BarclaysNegativeNegativehold
Nov 12, 2024JefferiesBuyBuyhold
Nov 12, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$5 $11 $17 $23 $29 $35 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.40$10.34$12.18$12.56$7.56----
Avg Forecast$16.08$16.82$17.68$18.56$19.59$21.01$21.45$22.22$22.74
High Forecast$16.75$17.52$18.41$18.98$19.86$22.39$30.68$31.07$23.91
Low Forecast$15.47$16.19$16.80$18.23$19.25$19.62$10.68$16.86$21.04
Surprise %-22.89%-38.53%-31.11%-32.33%-61.41%----

Revenue Forecast

$20B $24B $28B $32B $36B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$25.42B$25.98B$26.32B$28.19B$33.42B----
Avg Forecast$25.36B$26.00B$26.17B$28.12B$33.20B$34.61B$35.07B$35.60B$36.33B
High Forecast$26.18B$26.84B$27.00B$28.29B$33.48B$35.96B$35.08B$35.66B$37.75B
Low Forecast$24.63B$25.25B$25.17B$27.97B$32.91B$32.45B$35.06B$35.55B$34.23B
Surprise %0.24%-0.09%0.58%0.26%0.68%----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.26B$5.89B$6.55B$6.72B$4.09B----
Avg Forecast$6.37B$5.71B$6.49B$6.72B$10.52B$11.30B$7.13B$12.89B$12.24B
High Forecast$7.64B$6.85B$7.79B$8.06B$10.68B$12.05B$16.50B$16.71B$12.86B
Low Forecast$5.10B$4.56B$5.19B$5.37B$10.36B$10.56B$5.74B$9.07B$11.32B
Surprise %14.03%3.29%0.90%--61.12%----

AMGN Forecast FAQ

Is Amgen stock a buy?

Amgen stock has a consensus rating of Buy, based on 31 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Amgen is a favorable investment for most analysts.

What is Amgen's price target?

Amgen's price target, set by 31 Wall Street analysts, averages $304.67 over the next 12 months. The price target range spans from $294 at the low end to $315 at the high end, suggesting a potential 2.48% change from the previous closing price of $297.29.

How does Amgen stock forecast compare to its benchmarks?

Amgen's stock forecast shows a 2.48% upside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the drug manufacturers - general stocks industry (20.05%).

What is the breakdown of analyst ratings for Amgen over the past three months?

  • June 2025: 15.62% Strong Buy, 31.25% Buy, 43.75% Hold, 6.25% Sell, 3.12% Strong Sell.
  • May 2025: 15.62% Strong Buy, 28.12% Buy, 46.88% Hold, 6.25% Sell, 3.12% Strong Sell.
  • April 2025: 16.13% Strong Buy, 29.03% Buy, 45.16% Hold, 6.45% Sell, 3.23% Strong Sell.

What is Amgen’s EPS forecast?

Amgen's average annual EPS forecast for its fiscal year ending in December 2025 is $21.01, marking a 177.91% increase from the reported $7.56 in 2024. Estimates for the following years are $21.45 in 2026, $22.22 in 2027, and $22.74 in 2028.

What is Amgen’s revenue forecast?

Amgen's average annual revenue forecast for its fiscal year ending in December 2025 is $34.61B, reflecting a 3.55% increase from the reported $33.42B in 2024. The forecast for 2026 is $35.07B, followed by $35.6B for 2027, and $36.33B for 2028.

What is Amgen’s net income forecast?

Amgen's net income forecast for the fiscal year ending in December 2025 stands at $11.3B, representing an 176.33% increase from the reported $4.09B in 2024. Projections indicate $7.13B in 2026, $12.89B in 2027, and $12.24B in 2028.